Billiontoone Soars: Q2 Revenue Jumps 64%

Billiontoone announced robust financial results for the second quarter of 2026, concluding on June 30. The company experienced a significant 64% surge in revenue, reaching $109.4 million compared to $66.6 million in the previous year. This expansion was fueled by a 35% increase in test volumes and a 21% rise in average selling prices.

Financial performance demonstrated notable improvement. Gross profit climbed to $77.1 million with a gross margin of 70.5%. Importantly, Billiontoone achieved an operating income of $5.5 million, a substantial turnaround from the operating loss recorded in the second quarter of 2025. Net income available to common shareholders was $8.1 million, translating to $0.15 per diluted share.

Cash flow metrics also reflected positive momentum. The company generated $5.1 million in free cash flow, with cash from operations totaling $9.1 million. Billiontoone concluded the quarter holding $549 million in cash and equivalents, reinforcing its strong financial position.

Growth in key business segments was a major contributor. Prenatal revenue climbed 56% year-over-year to $95.8 million, while oncology revenue saw an exceptional increase of 176%, reaching $13.7 million. These figures highlight the company's successful commercial execution and expanding market presence.